MODD vs. LNSR, CODX, CTCX, ICU, RVP, AKLI, GBS, FEMY, NMTC, and MDAI
Should you be buying Modular Medical stock or one of its competitors? The main competitors of Modular Medical include LENSAR (LNSR), Co-Diagnostics (CODX), Carmell (CTCX), SeaStar Medical (ICU), Retractable Technologies (RVP), Akili (AKLI), GBS (GBS), Femasys (FEMY), NeuroOne Medical Technologies (NMTC), and Spectral AI (MDAI). These companies are all part of the "surgical & medical instruments" industry.
Modular Medical (NASDAQ:MODD) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
Modular Medical has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
LENSAR received 3 more outperform votes than Modular Medical when rated by MarketBeat users. However, 100.00% of users gave Modular Medical an outperform vote while only 38.46% of users gave LENSAR an outperform vote.
In the previous week, LENSAR had 8 more articles in the media than Modular Medical. MarketBeat recorded 9 mentions for LENSAR and 1 mentions for Modular Medical. Modular Medical's average media sentiment score of 0.93 beat LENSAR's score of 0.69 indicating that Modular Medical is being referred to more favorably in the media.
27.5% of Modular Medical shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 32.3% of Modular Medical shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Modular Medical has a net margin of 0.00% compared to LENSAR's net margin of -27.57%. LENSAR's return on equity of -36.53% beat Modular Medical's return on equity.
Modular Medical currently has a consensus price target of $4.25, suggesting a potential upside of 136.10%. LENSAR has a consensus price target of $8.00, suggesting a potential upside of 111.64%. Given Modular Medical's higher probable upside, research analysts plainly believe Modular Medical is more favorable than LENSAR.
Modular Medical has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Modular Medical beats LENSAR on 9 of the 16 factors compared between the two stocks.
Get Modular Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Modular Medical Competitors List
Related Companies and Tools
